Clinical

Dataset Information

Phase IIstudy of biweekly FOLFIRI+cetuximab treatment for unresectable KRAS-wild type colorectal cancer


ABSTRACT: Interventions: administration of cetuximab biweekly Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Colorectal Cancer

PROVIDER: 2626734 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR